Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

We applied a set of in silico and in vitro assays, compliant with the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm, to assess the risk of chloroquine (CLQ) or hydroxychloroquine (OH‐CLQ)‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin (ERT)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Transl Sci
Autores principales: Delaunois, Annie, Abernathy, Matthew, Anderson, Warren D., Beattie, Kylie A., Chaudhary, Khuram W., Coulot, Julie, Gryshkova, Vitalina, Hebeisen, Simon, Holbrook, Mark, Kramer, James, Kuryshev, Yuri, Leishman, Derek, Lushbough, Isabel, Passini, Elisa, Redfern, Will S., Rodriguez, Blanca, Rossman, Eric I., Trovato, Cristian, Wu, Caiyun, Valentin, Jean‐Pierre
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8014548/
https://ncbi.nlm.nih.gov/pubmed/33620150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.13011
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares